SPRB logo

Spruce Biosciences (SPRB) Company Overview

Profile

Full Name:

Spruce Biosciences, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

October 9, 2020

Indexes:

Not included

Description:

Spruce Biosciences is a biotechnology company focused on developing treatments for rare endocrine disorders. They aim to improve the lives of patients with conditions like congenital adrenal hyperplasia by creating innovative therapies that address unmet medical needs in the field of hormone-related diseases.

Events Calendar

Earnings

Next earnings date:

Mar 13, 2025

Recent quarterly earnings:

Nov 11, 2024

Recent annual earnings:

Mar 13, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Dec 16, 24 HC Wainwright & Co.
Neutral
Dec 12, 24 Guggenheim
Neutral
Dec 11, 24 RBC Capital
Sector Perform
Dec 11, 24 Oppenheimer
Perform
Dec 11, 24 JMP Securities
Market Perform
Nov 12, 24 RBC Capital
Sector Perform
Aug 19, 24 HC Wainwright & Co.
Neutral
Aug 13, 24 RBC Capital
Sector Perform
Jun 13, 24 Oppenheimer
Outperform
Jun 5, 24 HC Wainwright & Co.
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why
SPRB
zacks.comDecember 13, 2024

Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
SPRB
accesswire.comNovember 3, 2024

LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Take Part
Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Take Part
Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Take Part
SPRB
accesswire.comNovember 2, 2024

LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
SPRB
businesswire.comOctober 28, 2024

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the Guggenheim Securities Healthcare Innovation Conference on November 11, 2024, at 3:30 p.m. ET. Interested parties can access the live webca.

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
SPRB
accesswire.comOctober 27, 2024

LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out
Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out
Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out
SPRB
accesswire.comOctober 26, 2024

LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
SPRB
accesswire.comOctober 19, 2024

LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Shareholders To Reach Out
Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Shareholders To Reach Out
Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Shareholders To Reach Out
SPRB
accesswire.comOctober 18, 2024

LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Spruce Biosciences Inc For Securities Law Violations
SPRB
accesswire.comOctober 13, 2024

LOS ANGELES, CA / ACCESSWIRE / October 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Shareholders To Reach Out
Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Shareholders To Reach Out
Spruce Biosciences, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Shareholders To Reach Out
SPRB
accesswire.comOctober 12, 2024

LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Spruce Biosciences, Inc. ("Spruce" or "the Company") (NASDAQ:SPRB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

FAQ

  • What is the ticker symbol for Spruce Biosciences?
  • Does Spruce Biosciences pay dividends?
  • What sector is Spruce Biosciences in?
  • What industry is Spruce Biosciences in?
  • What country is Spruce Biosciences based in?
  • When did Spruce Biosciences go public?
  • Is Spruce Biosciences in the S&P 500?
  • Is Spruce Biosciences in the NASDAQ 100?
  • Is Spruce Biosciences in the Dow Jones?
  • When was Spruce Biosciences's last earnings report?
  • When does Spruce Biosciences report earnings?
  • Should I buy Spruce Biosciences stock now?

What is the ticker symbol for Spruce Biosciences?

The ticker symbol for Spruce Biosciences is NASDAQ:SPRB

Does Spruce Biosciences pay dividends?

No, Spruce Biosciences does not pay dividends

What sector is Spruce Biosciences in?

Spruce Biosciences is in the Healthcare sector

What industry is Spruce Biosciences in?

Spruce Biosciences is in the Biotechnology industry

What country is Spruce Biosciences based in?

Spruce Biosciences is headquartered in United States

When did Spruce Biosciences go public?

Spruce Biosciences's initial public offering (IPO) was on October 9, 2020

Is Spruce Biosciences in the S&P 500?

No, Spruce Biosciences is not included in the S&P 500 index

Is Spruce Biosciences in the NASDAQ 100?

No, Spruce Biosciences is not included in the NASDAQ 100 index

Is Spruce Biosciences in the Dow Jones?

No, Spruce Biosciences is not included in the Dow Jones index

When was Spruce Biosciences's last earnings report?

Spruce Biosciences's most recent earnings report was on Nov 11, 2024

When does Spruce Biosciences report earnings?

The next expected earnings date for Spruce Biosciences is Mar 13, 2025

Should I buy Spruce Biosciences stock now?

As of today, analysts generally recommend a 'Hold' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions